Hasco-Lek and Novasome receive subsidy from the Medical Research Agency

Together with our Novasome Research and Development Centre, we received a subsidy that will help us carry out an urgent and important project – developing a product for the treatment of type 2 diabetes

and conducting the clinical trials required to obtain a marketing authorisation.

The product we will develop is a response to the needs of the national and European pharmaceutical market and is in line with the pharmaceutical strategy for Europe and the move towards strengthening health protection systems in anticipation of crises.

We are more than happy that the grant we received will allow us to create a drug that will help patients!

Last posts

RafCycleTM by UPM Raflatac is a label waste recycling service where the film or paper release liner is processed and recirculated....
On May 1, 2023, there were changes in Hasco Group, which include the Management Boards of key companies: PPF Hasco-Lek S.A....
Together with our Novasome Research and Development Centre, we received a subsidy that will help us carry out an urgent and...

Last posts

RafCycleTM by UPM Raflatac is a label waste recycling service where the film or paper release liner is processed and recirculated....
On May 1, 2023, there were changes in Hasco Group, which include the Management Boards of key companies: PPF Hasco-Lek S.A....
Together with our Novasome Research and Development Centre, we received a subsidy that will help us carry out an urgent and...